image

The best stocks to buy since 1993

Latest issue now available

ImmuPharma

May 2018

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • IMM
  • Price:
  • 32p
ImmuPharma has announced Phase III trial results for Lupuzor, its compound to treat Lupus. Although Lupuzor demonstrated a superior response rate over the placebo group of all 202 patients, the high placebo/standard of care meant it did not meet statistical significance. Disappointing, not just for investors but more for sufferers. It’s not entirely a dead duck. A group of patients with autoantibodies biomarkers did demonstrate statistical significance (61.5% vs 47.3%, p = 0.0967) and it is possible the drug may still end up prescribed “off label” or in certain geographies.The company is gathering data each day to understand more on the trial and I am told they will share this with the market as soon as possib ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe